Symbols / CPRX
CPRX Chart
About
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.97B |
| Enterprise Value | 2.29B | Income | 217.56M | Sales | 578.20M |
| Book/sh | 7.47 | Cash/sh | 5.61 | Dividend Yield | — |
| Payout | 0.00% | Employees | 181 | IPO | — |
| P/E | 14.15 | Forward P/E | 9.32 | PEG | — |
| P/S | 5.14 | P/B | 3.24 | P/C | — |
| EV/EBITDA | 7.71 | EV/Sales | 3.95 | Quick Ratio | 6.19 |
| Current Ratio | 6.62 | Debt/Eq | 0.31 | LT Debt/Eq | — |
| EPS (ttm) | 1.71 | EPS next Y | 2.60 | EPS Growth | 20.00% |
| Revenue Growth | 15.30% | Earnings | 2026-02-25 | ROA | 17.74% |
| ROE | 27.52% | ROIC | — | Gross Margin | 83.13% |
| Oper. Margin | 44.66% | Profit Margin | 37.63% | Shs Outstand | 122.91M |
| Shs Float | 115.31M | Short Float | 9.19% | Short Ratio | 7.38 |
| Short Interest | — | 52W High | 26.58 | 52W Low | 19.05 |
| Beta | 0.73 | Avg Volume | 1.24M | Volume | 1.30M |
| Target Price | $34.57 | Recom | None | Prev Close | $24.11 |
| Price | $24.19 | Change | 0.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$34.57
Mean price target
2. Current target
$24.19
Latest analyst target
3. DCF / Fair value
$26.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.19
Low
$32.00
High
$38.00
Mean
$34.57
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-07 | main | Citigroup | Buy → Buy | $33 |
| 2025-03-03 | main | Baird | Outperform → Outperform | $32 |
| 2025-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-02-27 | reit | Stephens & Co. | Overweight → Overweight | $33 |
| 2025-02-04 | init | Baird | — → Outperform | $28 |
| 2025-01-10 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-01-09 | reit | B of A Securities | Buy → Buy | $30 |
| 2024-11-18 | init | Stephens & Co. | — → Overweight | $35 |
| 2024-11-11 | main | Truist Securities | Buy → Buy | $36 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-08-09 | main | Citigroup | Buy → Buy | $31 |
| 2024-08-09 | main | Truist Securities | Buy → Buy | $30 |
| 2024-06-06 | reit | Oppenheimer | Outperform → Outperform | $29 |
| 2024-06-03 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-05-10 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-03-27 | reit | Oppenheimer | Outperform → Outperform | $29 |
| 2024-03-22 | reit | Cantor Fitzgerald | Overweight → Overweight | $34 |
| 2024-03-14 | reit | Cantor Fitzgerald | Overweight → Overweight | $34 |
| 2024-03-14 | init | Citigroup | — → Buy | $27 |
- Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance ue, 24 Feb 2026 14
- Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Rare Disease Portfolio Developments - simplywall.st ue, 24 Feb 2026 18
- Ahead of Catalyst (CPRX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Nasdaq ue, 24 Feb 2026 14
- Catalyst Pharmaceuticals, Inc. (CPRX): Strong Buy Ratings and 43% Potential Upside Propel Investor Interest - DirectorsTalk Interviews Wed, 25 Feb 2026 04
- Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs (CPRX) - Seeking Alpha hu, 19 Feb 2026 16
- Liquidity Mapping Around (CPRX) Price Events - Stock Traders Daily ue, 24 Feb 2026 00
- Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for - Finviz Wed, 18 Feb 2026 16
- Catalyst Pharmaceuticals (CPRX) Stock Analysis: 42% Upside Potential Ignites Investor Interest - DirectorsTalk Interviews ue, 17 Feb 2026 20
- Is Catalyst Pharmaceuticals (CPRX) Stock Undervalued Right Now? - Nasdaq hu, 08 Jan 2026 08
- Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance hu, 19 Feb 2026 14
- Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance Wed, 17 Dec 2025 08
- Catalyst Pharmaceuticals (CPRX): Exploring Valuation as Shares Remain Steady and Investors Weigh Long-Term Growth - Yahoo Finance Mon, 03 Nov 2025 08
- Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance hu, 13 Nov 2025 08
- Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance Mon, 01 Dec 2025 08
- Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance ue, 03 Feb 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 687 | — | — | RUSSO GREGG | Officer | — | 2026-02-17 00:00:00 | D | nan |
| 1 | 7139 | — | — | KALB MICHAEL WAYNE | Chief Financial Officer | — | 2026-01-05 00:00:00 | D | nan |
| 2 | 42105 | — | — | DALY RICHARD J | Chief Executive Officer | — | 2026-01-05 00:00:00 | D | nan |
| 3 | 6667 | — | — | ELSBERND BRIAN D | Officer | — | 2025-12-29 00:00:00 | D | nan |
| 4 | 8667 | — | — | DEL CARMEN JEFFREY | Officer | — | 2025-12-29 00:00:00 | D | nan |
| 5 | 1334 | — | — | HARPER MOLLY | Director | — | 2025-12-29 00:00:00 | D | nan |
| 6 | 6667 | — | — | SUNDARAM PREETHI | Officer | — | 2025-12-29 00:00:00 | D | nan |
| 7 | 26334 | — | — | MCENANY PATRICK JAMES | Chairman of the Board | — | 2025-12-29 00:00:00 | D | nan |
| 8 | 1334 | — | — | DENKHAUS DONALD A | Director | — | 2025-12-29 00:00:00 | D | nan |
| 9 | 1334 | — | — | TIERNEY DAVID S | Director | — | 2025-12-29 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.23M | 737.86K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.24 | 0.24 | 0.21 | 0.25 |
| NormalizedEBITDA | 227.82M | 116.67M | 103.08M | 52.58M |
| TotalUnusualItems | 5.08M | 3.02M | ||
| TotalUnusualItemsExcludingGoodwill | 5.08M | 3.02M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | 163.89M | 71.41M | 83.08M | 39.48M |
| ReconciledDepreciation | 37.77M | 32.88M | 1.24M | 192.00K |
| ReconciledCostOfRevenue | 68.45M | 51.65M | 34.25M | 21.69M |
| EBITDA | 232.90M | 119.69M | 103.08M | 52.58M |
| EBIT | 195.12M | 86.81M | 101.84M | 52.38M |
| NetInterestIncome | 16.06M | 4.67M | ||
| NormalizedIncome | 160.04M | 69.12M | 83.08M | 39.48M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 163.89M | 71.41M | 83.08M | 39.48M |
| TotalExpenses | 296.61M | 311.39M | 112.36M | 88.45M |
| TotalOperatingIncomeAsReported | 195.12M | 86.81M | 101.84M | 52.38M |
| DilutedAverageShares | 124.94M | 113.75M | 111.38M | 107.80M |
| BasicAverageShares | 118.46M | 106.28M | 103.37M | 103.38M |
| DilutedEPS | 1.31 | 0.63 | 0.75 | 0.37 |
| BasicEPS | 1.38 | 0.67 | 0.80 | 0.38 |
| DilutedNIAvailtoComStockholders | 163.89M | 71.41M | 83.08M | 39.48M |
| NetIncomeCommonStockholders | 163.89M | 71.41M | 83.08M | 39.48M |
| NetIncome | 163.89M | 71.41M | 83.08M | 39.48M |
| NetIncomeIncludingNoncontrollingInterests | 163.89M | 71.41M | 83.08M | 39.48M |
| NetIncomeContinuousOperations | 163.89M | 71.41M | 83.08M | 39.48M |
| TaxProvision | 52.37M | 23.10M | 21.64M | 13.19M |
| PretaxIncome | 216.26M | 94.51M | 104.72M | 52.67M |
| OtherIncomeExpense | 5.08M | 3.02M | 2.88M | 282.00K |
| OtherNonOperatingIncomeExpenses | 7.70M | 2.88M | 282.00K | |
| GainOnSaleOfSecurity | 5.08M | 3.02M | ||
| NetNonOperatingInterestIncomeExpense | 16.06M | 4.67M | ||
| TotalOtherFinanceCost | -16.06M | -4.67M | ||
| OperatingIncome | 195.12M | 86.81M | 101.84M | 52.38M |
| OperatingExpense | 227.76M | 259.43M | 77.97M | 66.56M |
| DepreciationAmortizationDepletionIncomeStatement | 37.38M | 32.56M | 1.10M | 0.00 |
| DepreciationAndAmortizationInIncomeStatement | 37.38M | 32.56M | 1.10M | 0.00 |
| Amortization | 37.38M | 32.56M | 1.10M | 0.00 |
| AmortizationOfIntangiblesIncomeStatement | 37.38M | 32.56M | 1.10M | 0.00 |
| ResearchAndDevelopment | 12.65M | 93.15M | 19.79M | 16.94M |
| SellingGeneralAndAdministration | 177.74M | 133.71M | 57.09M | 49.63M |
| SellingAndMarketingExpense | 111.34M | 86.69M | 29.47M | 26.15M |
| GeneralAndAdministrativeExpense | 66.40M | 47.02M | 28.71M | 23.48M |
| OtherGandA | 45.92M | 34.25M | 22.54M | 19.02M |
| SalariesAndWages | 20.47M | 12.77M | 6.18M | 4.46M |
| GrossProfit | 422.89M | 346.24M | 179.81M | 118.95M |
| CostOfRevenue | 68.84M | 51.97M | 34.39M | 21.88M |
| TotalRevenue | 491.73M | 398.20M | 214.20M | 140.83M |
| OperatingRevenue | 491.73M | 398.20M | 214.20M | 140.83M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 120.88M | 107.12M | 105.26M | 102.99M |
| ShareIssued | 120.88M | 107.12M | 105.26M | 102.99M |
| TotalDebt | 3.19M | 3.56M | 3.89M | 4.20M |
| TangibleBookValue | 570.96M | 193.83M | 267.95M | 206.83M |
| InvestedCapital | 727.63M | 387.88M | 300.42M | 206.83M |
| WorkingCapital | 502.93M | 143.27M | 263.22M | 183.04M |
| NetTangibleAssets | 570.96M | 193.83M | 267.95M | 206.83M |
| CapitalLeaseObligations | 3.19M | 3.56M | 3.89M | 4.20M |
| CommonStockEquity | 727.63M | 387.88M | 300.42M | 206.83M |
| TotalCapitalization | 727.63M | 387.88M | 300.42M | 206.83M |
| TotalEquityGrossMinorityInterest | 727.63M | 387.88M | 300.42M | 206.83M |
| StockholdersEquity | 727.63M | 387.88M | 300.42M | 206.83M |
| GainsLossesNotAffectingRetainedEarnings | 64.00K | 14.00K | 24.00K | -148.00K |
| OtherEquityAdjustments | 64.00K | 14.00K | 24.00K | -148.00K |
| RetainedEarnings | 285.16M | 121.27M | 49.86M | -26.31M |
| AdditionalPaidInCapital | 442.29M | 266.49M | 250.43M | 233.19M |
| CapitalStock | 121.00K | 107.00K | 105.00K | 103.00K |
| CommonStock | 121.00K | 107.00K | 105.00K | 103.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 123.78M | 82.23M | 75.21M | 30.96M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.10M | 6.17M | 17.62M | 3.89M |
| OtherNonCurrentLiabilities | 315.00K | 485.00K | 14.06M | |
| DuetoRelatedPartiesNonCurrent | 14.06M | 0.00 | ||
| TradeandOtherPayablesNonCurrent | 0.00 | 2.50M | 14.06M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 2.79M | 3.19M | 3.56M | 3.89M |
| LongTermCapitalLeaseObligation | 2.79M | 3.19M | 3.56M | 3.89M |
| CurrentLiabilities | 120.68M | 76.06M | 57.59M | 27.06M |
| OtherCurrentLiabilities | 417.00K | 465.00K | 238.00K | 243.00K |
| CurrentDebtAndCapitalLeaseObligation | 402.00K | 369.00K | 337.00K | 308.00K |
| CurrentCapitalLeaseObligation | 402.00K | 369.00K | 337.00K | 308.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 10.75M | 8.88M | 5.13M | 4.04M |
| PayablesAndAccruedExpenses | 109.11M | 66.35M | 51.88M | 22.48M |
| CurrentAccruedExpenses | 88.04M | 38.28M | 26.08M | 19.63M |
| InterestPayable | 389.00K | 1.03M | 0.00 | 0.00 |
| Payables | 21.07M | 28.06M | 25.80M | 2.85M |
| OtherPayable | 3.58M | 12.54M | 13.13M | |
| DuetoRelatedPartiesCurrent | 13.13M | 0.00 | ||
| TotalTaxPayable | 894.00K | 729.00K | 8.70M | 79.00K |
| IncomeTaxPayable | 894.00K | 729.00K | 8.70M | 79.00K |
| AccountsPayable | 16.59M | 14.79M | 3.98M | 2.77M |
| TotalAssets | 851.41M | 470.11M | 375.63M | 237.79M |
| TotalNonCurrentAssets | 227.80M | 250.78M | 54.82M | 27.68M |
| NonCurrentPrepaidAssets | 9.00K | 9.00K | ||
| NonCurrentDeferredAssets | 45.98M | 36.54M | 18.74M | 23.70M |
| NonCurrentDeferredTaxesAssets | 45.98M | 36.54M | 18.74M | 23.70M |
| InvestmentsAndAdvances | 21.56M | 16.49M | 0.00 | |
| LongTermEquityInvestment | 21.56M | 16.49M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 156.67M | 194.05M | 32.47M | 0.00 |
| OtherIntangibleAssets | 156.67M | 194.05M | 32.47M | |
| NetPPE | 3.58M | 3.70M | 3.62M | 3.98M |
| AccumulatedDepreciation | -1.12M | -723.00K | -406.00K | -275.00K |
| GrossPPE | 4.70M | 4.43M | 4.02M | 4.25M |
| Leases | 991.00K | 991.00K | 980.00K | 980.00K |
| OtherProperties | 2.23M | 2.51M | 2.77M | 3.02M |
| MachineryFurnitureEquipment | 1.48M | 927.00K | 273.00K | 254.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 623.61M | 219.33M | 320.81M | 210.11M |
| OtherCurrentAssets | 1.03M | 351.00K | 354.00K | 327.00K |
| PrepaidAssets | 20.00M | 12.05M | 4.81M | 3.92M |
| Inventory | 19.54M | 15.64M | 6.80M | 7.87M |
| FinishedGoods | 9.58M | 9.16M | 1.26M | 929.00K |
| WorkInProcess | 3.44M | 4.57M | 5.54M | 5.17M |
| RawMaterials | 6.52M | 1.91M | 0.00 | 1.77M |
| Receivables | 65.49M | 53.65M | 10.79M | 6.72M |
| OtherReceivables | 11.00K | 138.00K | 354.00K | 105.00K |
| AccountsReceivable | 65.48M | 53.51M | 10.44M | 6.62M |
| CashCashEquivalentsAndShortTermInvestments | 517.55M | 137.64M | 298.39M | 191.27M |
| OtherShortTermInvestments | 0.00 | 19.82M | ||
| CashAndCashEquivalents | 517.55M | 137.64M | 298.39M | 171.44M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 239.25M | 61.86M | 116.02M | 59.35M |
| RepurchaseOfCapitalStock | -296.00K | 0.00 | 0.00 | -12.09M |
| IssuanceOfCapitalStock | 141.00M | 0.00 | 0.00 | |
| CapitalExpenditure | -556.00K | -81.74M | -29.00K | -1.02M |
| InterestPaidSupplementalData | 1.40M | 705.00K | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 68.45M | 50.46M | 7.67M | 3.00M |
| EndCashPosition | 517.55M | 137.64M | 298.39M | 171.44M |
| BeginningCashPosition | 137.64M | 298.39M | 171.44M | 130.24M |
| ChangesInCash | 379.92M | -160.76M | 126.95M | 41.21M |
| FinancingCashFlow | 140.66M | -10.86M | 1.69M | -8.14M |
| CashFlowFromContinuingFinancingActivities | 140.66M | -10.86M | 1.69M | -8.14M |
| NetOtherFinancingCharges | -13.55M | -13.65M | -7.88M | -153.00K |
| ProceedsFromStockOptionExercised | 13.52M | 2.79M | 9.57M | 4.10M |
| NetCommonStockIssuance | 140.70M | 0.00 | 0.00 | -12.09M |
| CommonStockPayments | -296.00K | 0.00 | 0.00 | -12.09M |
| CommonStockIssuance | 141.00M | 0.00 | 0.00 | |
| InvestingCashFlow | -556.00K | -293.50M | 9.21M | -11.02M |
| CashFlowFromContinuingInvestingActivities | -556.00K | -293.50M | 9.21M | -11.02M |
| NetOtherInvestingChanges | -198.29M | -10.00M | ||
| NetInvestmentPurchaseAndSale | 0.00 | -13.46M | 19.24M | -10.00M |
| SaleOfInvestment | 0.00 | 0.00 | 19.24M | 0.00 |
| PurchaseOfInvestment | 0.00 | -13.46M | 0.00 | -10.00M |
| NetIntangiblesPurchaseAndSale | 0.00 | -81.51M | 0.00 | 0.00 |
| PurchaseOfIntangibles | 0.00 | -81.51M | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -556.00K | -231.00K | -29.00K | -1.02M |
| PurchaseOfPPE | -556.00K | -231.00K | -29.00K | -1.02M |
| OperatingCashFlow | 239.81M | 143.60M | 116.05M | 60.37M |
| CashFlowFromContinuingOperatingActivities | 239.81M | 143.60M | 116.05M | 60.37M |
| ChangeInWorkingCapital | 30.91M | -37.32M | 13.73M | 5.02M |
| ChangeInOtherCurrentLiabilities | -369.00K | -338.00K | -307.00K | 864.00K |
| ChangeInPayablesAndAccruedExpense | 55.65M | 16.62M | 17.60M | 4.03M |
| ChangeInAccruedExpense | 53.85M | 5.80M | 16.39M | 5.52M |
| ChangeInPayable | 1.80M | 10.82M | 1.21M | -1.49M |
| ChangeInAccountPayable | 1.80M | 10.82M | 1.21M | -1.49M |
| ChangeInPrepaidAssets | -8.50M | -5.79M | -807.00K | 3.98M |
| ChangeInInventory | -3.90M | -4.74M | 1.06M | -3.22M |
| ChangeInReceivables | -11.96M | -43.08M | -3.82M | -632.00K |
| ChangesInAccountReceivables | -11.96M | -43.08M | -3.82M | -632.00K |
| OtherNonCashItems | -557.00K | 83.22M | 4.39M | 287.00K |
| StockBasedCompensation | 22.25M | 14.25M | 7.91M | 6.07M |
| UnrealizedGainLossOnInvestmentSecurities | -5.08M | -3.02M | 0.00 | 0.00 |
| DeferredTax | -9.39M | -17.82M | 4.94M | 9.32M |
| DeferredIncomeTax | -9.39M | -17.82M | 4.94M | 9.32M |
| DepreciationAmortizationDepletion | 37.77M | 32.88M | 1.24M | 192.00K |
| DepreciationAndAmortization | 37.77M | 32.88M | 1.24M | 192.00K |
| AmortizationCashFlow | 37.38M | 32.56M | 1.10M | 0.00 |
| AmortizationOfIntangibles | 37.38M | 32.56M | 1.10M | 0.00 |
| Depreciation | 397.00K | 316.00K | 141.00K | 192.00K |
| OperatingGainsLosses | 262.00K | 762.00K | 292.00K | |
| GainLossOnInvestmentSecurities | 762.00K | |||
| GainLossOnSaleOfPPE | 262.00K | 247.00K | 292.00K | |
| NetIncomeFromContinuingOperations | 163.89M | 71.41M | 83.08M | 39.48M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CPRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|